Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial

Vaccine

Volumn 33, Issue 21, 2015, Pages 2485-2492

  Cadorna Carlos, Josefina B ^a   Nolan, Terry ^b   Borja Tabora, Charissa Fay ^c   Santos, Jaime ^d   Montalban, M Cecilia ^e   de Looze, Ferdinandus J ^f,g   Eizenberg, Peter ^h   Hall, Stephen ⁱ   Dupuy, Martin ^j   Hutagalung, Yanee ^k   Pépin, Stéphanie ^j   Saville, Melanie ^j  

^a University of the East   (Philippines)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^d Philippine Children's Medical Center   (Philippines)

^e Our Lady of Remedies Clinic   (Philippines)

^f AusTrials   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h Doctors of Ivanhoe   (Australia)

ⁱ Emeritus Research   (Australia)

^j SANOFI PASTEUR   (France)

^k Sanofi Pasteur Clinical Development Department   (Singapore)

more..

Author keywords

Immunogenicity; Influenza; Quadrivalent; Safety; Trivalent; Vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUSTRALIA; CHILD; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY (TOPIC); MYALGIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PHILIPPINES; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; TREMOR; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; AUSTRALIA; CHILD; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PHILIPPINES; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84928581376     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.065     Document Type: Article

References (26)

1. Ambrose C.S., Levin M.J. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012, 8(1):81-88.
2. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28(Suppl. 4):D45-D53.
3. Traynor K. First quadrivalent flu vaccine approved. Am J Health Syst Pharm 2012, 69(7):538.
4. Centers for Disease Control and Prevention Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 2013, 62(RR-07):1-43.
5. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30(11):1993-1998.
6. Lee B.Y., Bartsch S.M., Willig A.M. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012, 30(52):7443-7446.
7. Beran J., Peeters M., Dewe W., Raupachova J., Hobzova L., Devaster J.M. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013, 13:224.
8. Block S.L., Falloon J., Hirschfield J.A., Krilov L.R., Dubovsky F., Yi T., et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012, 31(7):745-751.
9. Block S.L., Yi T., Sheldon E., Dubovsky F., Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011, 29(50):9391-9397.
10. Domachowske J.B., Pankow-Culot H., Bautista M., Feng Y., Claeys C., Peeters M., et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013, 207(12):1878-1887.
11. Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013, 31(5):770-776.
12. Pepin S., Donazzolo Y., Jambrecina A., Salamand C., Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013, 31(47):5572-5578.
13. WHO Global Influenza Surveillance Network Manual for the laboratory diagnosis and virological surveillance of influenza 2011, WHO Press, Geneva.
14. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
15. Cox R.J. Correlates of protection to influenza virus, where do we go from here?. Hum Vaccin Immunother 2013, 9(2):405-408.
16. Ohmit S.E., Petrie J.G., Cross R.T., Johnson E., Monto A.S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011, 204(12):1879-1885.
17. Govaert T.M., Sprenger M.J., Dinant G.J., Aretz K., Masurel N., Knottnerus J.A. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994, 12(13):1185-1189.
18. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176(10):6333-6339.
19. Black S., Nicolay U., Vesikari T., Knuf M., Del Giudice G., Della Cioppa G., et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011, 30(12):1081-1085.
20. Davies J.R., Grilli E.A. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989, 102(2):325-333.
21. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
22. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
23. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.
24. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(13):1343-1351.
25. Kim S.Y., Kim Y.K., Eun B.W., Kim N.H., Kang E.K., Lee B.S., et al. Evaluation of immunogenicity of the 2008-2009 seasonal influenza vaccines by microneutralization test. Korean J Pediatr 2012, 55(12):474-480.
26. Talaat K.R., Karron R.A., Liang P.H., McMahon B.A., Luke C.J., Thumar B., et al. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses 2013, 7(1):66-73.